Navigation Links
MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
Date:5/21/2013

ROCKVILLE, Md., May 21, 2013 /PRNewswire/ -- MacroGenics, Inc. today announced that an abstract titled, "Phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in patients with advanced solid tumors expressing the HER2 oncoprotein," will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology during the Developmental Therapeutics - Immunotherapy Oral Abstract Session on Monday, June 3 at 4:15 – 4:30 PM.  The presentation will describe the results of a first-in-human study of MacroGenics' next-generation anti-HER2 monoclonal antibody, margetuximab, which is being developed to treat HER2-expressing tumors.  

MacroGenics has optimized the Fc region of margetuximab to increase cancer cell killing via Antibody-Dependent Cell-mediated Cytotoxicity (ADCC).  Margetuximab also has shown improved control of tumor growth in human tumor xenograft models in mice as compared to that of anti-HER2 antibodies with a wild type Fc region.  A development goal for margetuximab is to enable the treatment of a broader population of patients than those eligible for treatment with current HER2-targeted therapies.

MacroGenics also announced that the first patient has received study drug in a Phase 2 clinical study evaluating margetuximab in patients with metastatic breast cancer.  This study is designed to evaluate the activity of margetuximab in up to 41 patients with metastatic breast cancer whose tumors express a moderate level of the oncoprotein, HER2, represented by a 2+ score by immunohistochemistry.  These tumors must also lack evidence of HER2 gene amplification as determined by FISH testing.  The trial is being conducted at six sites across the United States.  For more information on the clinical trial, please see www.clinicaltrials.gov.

"To date, the results of our Phase 1 s
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
2. Revolutionary Science Announces New Automatic and Manual Colony Counting Products
3. Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing
4. SoundConnect Announces Microsoft Lync Release in Canada
5. GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit
6. Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes
7. YouTube Channel on SEO Tips Surpasses 175,000 Views, Announces JM Internet Group
8. Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech
9. DNA Genotek Inc. Announces Spit for Africa Program
10. Metabolic Solutions Development Company announces publication of data describing a new drug target for diabetes
11. Discovery Labs Announces Completion of $14.25 Million Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Convey Computer , the leader in ... State University won first place in the 2014 ... the team’s solution achieved the highest overall performance in ... place finisher. , Experts from all segments of the ... challenge, using a variety of design tools, hardware and ...
(Date:10/20/2014)... , Oct. 20, 2014 PureTech ... company tackling big healthcare problems, announced today the ... round, with participation from Invesco Perpetual, a $120 ... used to drive PureTech,s existing pipeline forward and ... "PureTech has the scientific creativity to really go ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 ... Industry Meeting (ABIM). ABIM will take ... More information about ABIM 2014 is now ... , Delegates representing companies and organizations from ... and obtain information on the latest products ...
(Date:10/19/2014)... 2014 The report "Chocolate, Cocoa Beans, ... Prices, Geography Trend and Forecast (2011 - 2016)," ... geography and studies the major market drivers, restraints, and ... and Asia. , The global chocolate market is expected ... in 2016 at an estimated CAGR of 2.7% from ...
Breaking Biology Technology:Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4
... Meeting October 23, IRVINE, California, October 16 ... orthobiologics company, today announced the,interim tabulation results of ... and adjourned to October 23, 2007. Prior ... percent,of the shares entitled to vote, voted for ...
... Fresh data on mass spectrometry are presented in ... derived from ortho-, meta-, and para-hydroxyphenyl carbaldehydes, ketones, ... and his colleagues in the Center for Mass ... According to a study, Collision-induced dissociation (CID) mass ...
... 15 The Liver Meeting is the premier,meeting in ... on new drugs, novel treatments, and the results from ... have some form of liver disease,and the diseases strike ... There are now numerous treatments,for both hepatitis B and ...
Cached Biology Technology:IsoTis Reports Interim Results of Vote for Integra Merger 2IsoTis Reports Interim Results of Vote for Integra Merger 3IsoTis Reports Interim Results of Vote for Integra Merger 4Stevens researchers provide new information about mass spectrometry 2
(Date:10/15/2014)... bacterial pneumonia in female mice to an enzyme activated ... naturally more resistant to respiratory infections than males. Now, ... resistance to bacterial pneumonia in female mice is linked ... also show that this enzyme is ultimately activated by ... The team, lead by Professor Lester Kobzik at the ...
(Date:10/14/2014)... shows SIRT6—a protein known to inhibit the growth ... skin cancers by turning on an enzyme that increases ... Previously considered protective, SIRT6 is part of a family ... stability and prevent some of the genetic flaws associated ... lead to cancer. This study, in the journal,s October ...
(Date:10/14/2014)... October 14, 2014 – High doses of fish oil supplements, ... a common type of irregular heartbeat in which the heart ... results of the AFFORD trial led by the Montreal Heart ... College of Cardiology on October 7th. , For the ... therapy were randomly assigned to 4 grams of fish oil ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
... 2013   EyeLock Inc. , a market leader of ... Michael Fiorito as Vice President of ... expansion of the EyeLock,s proprietary iris authentication solutions ... role, Fiorito will be responsible for managing all ...
... August 15, 2013 German researchers have identified four ... and contribute to the accurate prediction of patient outcomes. ... The Journal of Molecular Diagnostics . Current ... size, and number of foci, have limited usefulness for ...
... People who often recall their dreams respond more strongly ... the great mysteries of human cognition. It is still not ... brain produce them. A major difficulty for studying dreams is ... Perrine Ruby and colleagues from the Lyon Neuroscience Research ...
Cached Biology News:EyeLock Appoints Michael Fiorito Vice President of Enterprise Accounts 2MicroRNAs have diagnostic and prognostic potential in urinary bladder cancer 2Frontiers news briefs: Aug. 13 2Frontiers news briefs: Aug. 13 3
... Features Convenient platform for tube handling ... 96 x 0.2ml V-bottom tubes - ... Plates - Thermo-Fast® 96 Non-Skirted Plate ... - 48 x 0.5ml Thermo-Tubes Multiple workstations ...
... 96 well Magnetic-Ring Stand is designed for ... U-bottom microplates. The stand has a plastic ... microtiter plate footprint. The use of 96 ... and easy magnetic separation. With this magnetic ...
... - 5 units/µL ,• High specific activity ... Leaves an 'A' overhang ,• Processes ... very high activity in primer extension and ... quality of the enzyme, each lot has ...
Taq DNA Polymerase (T. aquaticus), 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzyme...
Biology Products: